Year |
Citation |
Score |
2024 |
Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, ... ... Gustafson WC, et al. ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Reports. 43: 113927. PMID 38451815 DOI: 10.1016/j.celrep.2024.113927 |
0.785 |
|
2022 |
Morales J, Allegakoen DV, Garcia JA, Kwong K, Sahu PK, Fajardo DA, Pan Y, Horlbeck MA, Weissman JS, Gustafson WC, Bivona TG, Sabnis AJ. GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion positive rhabdomyosarcoma. Jci Insight. PMID 36282590 DOI: 10.1172/jci.insight.162207 |
0.364 |
|
2021 |
Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, ... ... Gustafson WC, et al. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia (New York, N.Y.). 23: 624-633. PMID 34107377 DOI: 10.1016/j.neo.2021.05.003 |
0.598 |
|
2021 |
Wolpaw AJ, Bayliss R, Büchel G, Dang CV, Eilers M, Gustafson WC, Hansen GM, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, et al. Drugging the 'undruggable' MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers. Cancer Research. PMID 33509943 DOI: 10.1158/0008-5472.CAN-20-3108 |
0.555 |
|
2019 |
Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, ... ... Gustafson WC, et al. Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface. Cancer Research. PMID 31501192 DOI: 10.1158/0008-5472.Can-19-1112 |
0.449 |
|
2019 |
Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, Xu L, Zhou W, Zheng T, Luo Z, Berry KP, Pribnow A, Smith SM, Fuller C, Jones BV, ... ... Gustafson WC, et al. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. PMID 31474569 DOI: 10.1016/J.Ccell.2019.07.009 |
0.6 |
|
2019 |
Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for I-MIBG therapy of neuroblastoma using I-MIBG PET/CT. Medical Physics. PMID 30761545 DOI: 10.1002/Mp.13446 |
0.307 |
|
2019 |
Zhao G, Muldoon D, Mo X, Tang C, Fu H, Gustafson WC, Weiss WA, Nicolaides T. Ther-17. Braf-V600E Degradation As A Therapeutic Strategy In Braf-V600E Mutant Gliomas Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.224 |
0.671 |
|
2019 |
Menard M, McHenry L, Nasholm N, Wong-Michalak S, Lu E, Simonds E, Gustafson WC, Weiss WA. Immu-06. Investigating Immunosuppressive Mechanisms In The Tumor Microenvironment Of High-Risk Neuroblastoma; An Immunocompetent, Mycn-Driven, Non-Germline Gem Model Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.127 |
0.731 |
|
2017 |
Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. The Journal of Clinical Investigation. PMID 29202477 DOI: 10.1172/Jci90793 |
0.644 |
|
2017 |
Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 31: 424-435. PMID 28292440 DOI: 10.1016/J.Ccell.2017.01.014 |
0.802 |
|
2016 |
Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 29: 536-47. PMID 27050099 DOI: 10.1016/J.Ccell.2016.03.001 |
0.726 |
|
2016 |
Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, et al. Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging. PMID 27044383 DOI: 10.1007/S00259-016-3381-X |
0.329 |
|
2015 |
Meyerowitz JG, Weiss WA, Gustafson WC. A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. Molecular & Cellular Oncology. 2: e975641. PMID 27308435 DOI: 10.4161/23723556.2014.975641 |
0.792 |
|
2015 |
Yu D, Dong Z, Gustafson WC, Ruiz-González R, Signor L, Marzocca F, Borel F, Klassen MP, Makhijani K, Royant A, Jan YN, Weiss WA, Guo S, Shu X. Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo. Protein Science : a Publication of the Protein Society. PMID 26549191 DOI: 10.1002/Pro.2843 |
0.416 |
|
2015 |
Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging. PMID 26338179 DOI: 10.1007/S00259-015-3179-2 |
0.343 |
|
2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology. 5: 111. PMID 26029667 DOI: 10.3389/Fonc.2015.00111 |
0.815 |
|
2015 |
Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA. The genetics of splicing in neuroblastoma. Cancer Discovery. 5: 380-95. PMID 25637275 DOI: 10.1158/2159-8290.Cd-14-0892 |
0.774 |
|
2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer Frontiers in Oncology. 5. DOI: 10.3389/fonc.2015.00111 |
0.682 |
|
2014 |
Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, et al. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Reports. 9: 1034-46. PMID 25437558 DOI: 10.1016/J.Celrep.2014.09.046 |
0.778 |
|
2014 |
Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 26: 414-27. PMID 25175806 DOI: 10.1016/J.Ccr.2014.07.015 |
0.788 |
|
2014 |
Yu D, Gustafson WC, Han C, Lafaye C, Noirclerc-Savoye M, Ge WP, Thayer DA, Huang H, Kornberg TB, Royant A, Jan LY, Jan YN, Weiss WA, Shu X. An improved monomeric infrared fluorescent protein for neuronal and tumour brain imaging. Nature Communications. 5: 3626. PMID 24832154 DOI: 10.1038/Ncomms4626 |
0.413 |
|
2014 |
Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, N.Y.). 343: 189-93. PMID 24336570 DOI: 10.1126/Science.1239947 |
0.589 |
|
2014 |
Gustafson WC, Meyerowitz JG, Nekritz EA, Charron E, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Abstract PR08: Drugging MYCN protein stability through an allosteric transition in Aurora kinase A Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr08 |
0.817 |
|
2014 |
Meyerowitz JG, Gustafson WC, Nekritz E, Swartling F, Shokat KM, Ruggero D, Weiss WA. Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B78 |
0.818 |
|
2014 |
Batra V, Chacko A, Gagliardi M, Hou C, Mikitsh JL, Freifelder RH, Kachur A, LeGeyt BC, Schmitz A, Toto L, Vaidyanathan G, Zalutsky MR, Matthay KK, Weiss WA, Gustafson WC, et al. Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B48 |
0.531 |
|
2014 |
Chen J, Hackett CS, Zhang S, Song YK, Molinaro A, Quigley DA, Balmain A, Gustafson WC, Dyke TAV, Kwok P, Khan J, Weiss WA. Abstract 3413: A genetic analysis of splicing in neuroblastoma identifies opposing functions for FUBP1 splice variants in MYC regulation Cancer Research. 74: 3413-3413. DOI: 10.1158/1538-7445.Am2014-3413 |
0.78 |
|
2014 |
Gustafson WC, Meyerowitz JG, Nekritz EA, Charron EA, Chanthery Y, Simonds E, Matthay K, Hertz N, Shokat K, Weiss WA. Abstract 2688: Drugging MYCN through an allosteric transition in Aurora A kinase Cancer Research. 74: 2688-2688. DOI: 10.1158/1538-7445.Am2014-2688 |
0.78 |
|
2013 |
Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 24: 438-49. PMID 24135280 DOI: 10.1016/J.Ccr.2013.09.004 |
0.786 |
|
2013 |
Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, Mcdermott U, Benes CH, Kung AL, Weiss WA, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discovery. 3: 309-323. PMID 23430699 DOI: 10.1158/2159-8290.Cd-12-0418 |
0.805 |
|
2013 |
Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, et al. Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Research. 73: 4622-4622. DOI: 10.1158/1538-7445.Am2013-4622 |
0.636 |
|
2012 |
Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America. 109: 12722-7. PMID 22802621 DOI: 10.1073/Pnas.1202492109 |
0.659 |
|
2012 |
Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 735-42. PMID 22382618 DOI: 10.1007/S11307-012-0552-4 |
0.508 |
|
2012 |
Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science Translational Medicine. 4: 115ra3. PMID 22218692 DOI: 10.1126/scitranslmed.3002977 |
0.795 |
|
2011 |
Chanthery YH, Gustafson WC, Weiss WA. Abstract 1558: Paracrine signaling through Mycn enhances tumor-vascular microenvironment in neuroblastoma Cancer Research. 71: 1558-1558. DOI: 10.1158/1538-7445.Am2011-1558 |
0.82 |
|
2010 |
Gustafson WC, Weiss WA. Addiction to B-MYB. Oncotarget. 1: 235-6. PMID 21304174 DOI: 10.18632/oncotarget.100807 |
0.347 |
|
2010 |
Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene. 29: 1249-59. PMID 20101214 DOI: 10.1038/Onc.2009.512 |
0.615 |
|
2010 |
Gustafson WC, Weiss WA. Addiction to B-MYB Oncotarget. 1: 235-236. DOI: 10.18632/Oncotarget.132 |
0.573 |
|
2005 |
Gustafson WC, De Berry BB, Evers BM, Chung DH. Role of gastrointestinal hormones in neuroblastoma. World Journal of Surgery. 29: 281-6. PMID 15706438 DOI: 10.1007/S00268-004-7815-4 |
0.378 |
|
2004 |
Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I, Fields AP, Brasier AR. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. The Journal of Biological Chemistry. 279: 35604-15. PMID 15155749 DOI: 10.1074/Jbc.M401851200 |
0.371 |
|
2004 |
Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. The Journal of Biological Chemistry. 279: 9400-8. PMID 14670960 DOI: 10.1074/Jbc.M312840200 |
0.442 |
|
2003 |
Fields AP, Murray NR, Gustafson WC. Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models. Methods in Molecular Biology (Clifton, N.J.). 233: 539-53. PMID 12840533 DOI: 10.1385/1-59259-397-6:539 |
0.391 |
|
2003 |
Fields AP, Gustafson WC. Protein kinase C in disease: cancer. Methods in Molecular Biology (Clifton, N.J.). 233: 519-37. PMID 12840532 DOI: 10.1385/1-59259-397-6:519 |
0.404 |
|
Show low-probability matches. |